Biotherapeutic for the Treatment of Atopic Dermatitis in Client-Owned Dogs Current Status: Open and enrolling
Principal Investigator: Sheila M. F. Torres, DVM, MS, PhD, DACVD
Contact:
Sara Pracht, CVT - phone: 612-626-3574, e-mail prach011@umn.edu
Dr. Torres - phone: 612-624-3746, e-mail torre009@umn.edu
We are now enrolling dogs with year-round atopic dermatitis for a study to evaluate the safety and efficacy of an investigational drug compared to a placebo in controlling the clinical signs associated with this condition. This new drug is injectable. Dogs must be diagnosed with year-round allergies and must be a year old or more. Allergy testing is not required. Dogs with food allergies are allowed if they are maintained on their hypoallergenic diet. All study visits, diagnostic lab work, and the study drug or placebo will be offered at no cost to the owner. Owners will also receive a $300 cash incentive upon completion of the study. Study visits include Day 0 and Day 14 (injections) then follow ups at Day 28 (4 weeks) and Day 42 (6 weeks). The same owner should be willing to accompany the dog to these visits in order to consistently evaluate the dog's itchiness. Dogs cannot be on any treatments containing glucocorticoids, antihistamine, cyclosporine A, or other anti-inflammatory or immunosuppressive drugs during the course of the study. We will ask you to withdraw these drugs for a certain time prior to enrollment.
For more information, please contact Sara Pracht or Dr. Torres. | 
Dr. Sheila Torres and patient |
